BioNTech’s Bold Bet Beyond the Vaccine: Can Cancer Therapies Turn the Tide?
BioNTech is navigating financial challenges as COVID-19 vaccine demand declines, reporting a €700 million net loss for 2024 due to heavy investment in clinical studies. The company's Q4 2024 earnings…